A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients
In this study, an UPLC-MS/MS method was established to determine the concentration of pyrotinib in human plasma. A population pharmacokinetic model of pyrotinib in HER2 positive breast cancer patients suggested that low serum total protein reduced the clearance rate of pyrotinib in patients. Clinical medical staff should pay attention to the liver function of patients with abnormal serum total protein and be alert to the occurrence of adverse drug reactions.
Authors
- Xiaonan Gao (ORCID: https://orcid.org/0000-0002-8939-7600)
- Zhangying Feng (ORCID: https://orcid.org/0000-0002-7881-6937)
- Jinglin Gao (ORCID: https://orcid.org/0000-0003-4662-2764)
- Hongxin Qie
- Rui Feng (ORCID: https://orcid.org/0000-0002-4523-9344)
- Jing Bai (ORCID: https://orcid.org/0000-0001-5412-7793)
- Yunfang Zhu
- Yuxiang Xu (ORCID: https://orcid.org/0009-0009-3071-426X)
- Mingxia Wang (ORCID: https://orcid.org/0000-0003-2340-8941)
- Haopeng Zhao
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.3389/fphar.2024.1432944
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Natural Science Foundation of Hebei Province